6-K 1 ea0262181-6k_meihua.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number 001-41291

MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.

(Translation of registrant’s name into English)

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Other Events

Attached hereto as Exhibit 99.1 and Exhibit 99.2 are a Notice of Extraordinary General Meeting of Shareholders (the “Notice”) and a Proxy Card, respectively, of Meihua International Medical Technologies Co., Ltd. (the “Company”) relating to the Company’s extraordinary general meeting of shareholders (the “EGM”) to be held on November 3, 2025.

Where to Find Additional Information

The Company is a foreign private issuer. As such, the Notice is not subject to review and comment by the Securities and Exchange Commission (the “SEC”).

Shareholders are urged to carefully read the Notice, because it contains important information about the Company and the EGM. Copies of Notice and other documents filed or submitted by the Company will be available at the website maintained by the SEC at www.sec.gov. Shareholders may obtain a copy of such filings, free of charge, from the Company’s website at http://ir.meihuamed.com/ or by writing to us at 88 Tongda Road, Touqiao Town, Guangling District, Yangzhou, 225000, People’s Republic of China.

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of the Company in connection with the EGM. Information regarding certain directors and executive officers of the Company is available in the Company’s documents filed with or submitted to the SEC. Other information regarding the participants in the proxy solicitation and descriptions of their direct and indirect interests, by security holdings or otherwise, are set forth in the Notice filed herewith.

Exhibits

Exhibit No.		Description
99.1		Notice of Extraordinary General Meeting of Shareholders and Proxy Statement
99.2		Proxy Card

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MEIHUA INTERNATIONAL MEDICAL TECHNOLOGIES CO., LTD.

Date: October 23, 2025	By:	/s/ Leyi Lee
		Name:	Leyi Lee
		Title:	Chief Executive Officer

SEC Form 6-K filed by Meihua International Medical Technologies Co. Ltd.